ARTICLE | Company News
Quanterix, Beth Israel Deaconess Medical Center, Forsyth Institute deal
February 20, 2012 8:00 AM UTC
The entities partnered to use Quanterix's Single Molecule Array (SiMoA) technology to validate low abundance biomarkers useful in identifying individuals with active tuberculosis (TB). The partners will then develop a diagnostic based on the biomarkers. Forsyth will have rights to intellectual property related to the biomarkers. The partnership is supported by a grant from the Bill & Melinda Gates Foundation announced earlier this month (see BioCentury, Feb. 13). ...